Abstract: SA-PO0661
Early Real-World Outcomes Among US Patients (Pts) with IgAN Receiving Atrasentan: APPRISE-IgAN Data Platform
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - Other
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Narayanan, Mohanram, Baylor Scott & White Health, Dallas, Texas, United States
- Ndife, Briana C., Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Trenz, Helen, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Dance, Manny, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Haile-Meskale, Ruth, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Stephens, Neema, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
- Buchan, Claire, Asclepius Analytics, New York, New York, United States
- Buchan, Tayler, Asclepius Analytics, New York, New York, United States
- Baraka, Eugene, Asclepius Analytics, New York, New York, United States
- Canetta, Pietro A., Columbia University, New York, New York, United States
Background
A Pt Platform for Real-world data on Iptacopan and Atrasentan in the United StatEs for pts with IgAN (APPRISE-IgAN) captures real-world data on US pts with IgAN prescribed atrasentan (selective endothelin type A receptor antagonist) and/or iptacopan (complement factor B inhibitor). We report clinical outcomes of pts on atrasentan enrolled to date.
Methods
Data from adults providing consent for enrollment from Jul 2025–Mar 2026 were sourced from specialty pharmacy and medical records. Duration of therapy was from atrasentan initiation (index) to discontinuation or data cutoff. Treatment adherence was assessed by ratio of days’ supply to days of follow-up (proportion of days covered; PDC). Outcomes for this analysis were changes in urine protein-creatinine ratio and hematuria from pre-index up to 3–6 months post-index.
Results
Of 53 enrolled pts, median (interquartile range, IQR) age was 48.8 (41.5–65.7) years, 58% were male, and 68% had commercial insurance. Median (IQR) duration of atrasentan therapy was 4.2 (2.4–5.8) months, PDC was 98.5% (93.0%–100.0%), and 3 pts discontinued by data cutoff. Of 43 pts with clinical data, 79% and 47% had prior sodium-glucose cotransporter-2 inhibitor (SGLT2i) and corticosteroid use, respectively. Of 24 pts with complete Oxford MEST-C scores, 67% had mesangial or endocapillary hypercellularity or crescents (M1, E1, or C1/C2); 92% had segmental glomerulosclerosis or tubular atrophy/interstitial fibrosis (S1 or T1/T2). Proteinuria and hematuria values improved by 1–3 months, sustained through 6 months (Table 1).
Conclusion
In this real-world study, atrasentan showed meaningful proteinuria and hematuria reduction in a subgroup of SGLT2i-experienced population with IgAN, suggesting early clinical benefit. Ongoing data collection will provide further information.
Acknowledgment
Medical writing support and editorial support were provided by Julia L. de Amorim, PhD (BOLDSCIENCE Inc.), and were funded by Novartis Pharmaceuticals Corporation. This abstract was developed in accordance with Good Publication Practice (GPP) guidelines. The authors had full control of the content and made the final decision on all aspects of this publication.
Funding
- Commercial Support – Novartis Pharmaceuticals Corporation